The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ELEVEN BIOTHERAPEUTICS INC | COM | 286221106 | 2,464 | 1,466,417 | SH | SOLE | 1,466,417 | 0 | 0 | ||
| T2 BIOSYSTEMS INC | COM | 89853L104 | 5,852 | 741,755 | SH | SOLE | 741,755 | 0 | 0 | ||
| SERES THERAPEUTICS INC | COM | 81750R102 | 368,438 | 12,682,876 | SH | SOLE | 12,682,876 | 0 | 0 | ||
| EDITAS MEDICINE INC | COM | 28106W103 | 120,910 | 4,955,316 | SH | SOLE | 4,955,316 | 0 | 0 | ||
| SYROS PHARMACEUTICALS INC | COM | 87184Q107 | 87,241 | 4,806,656 | SH | SOLE | 4,806,656 | 0 | 0 | ||